Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam s Underwriters Exercise Over-Allotment Option

NEW YORK, June 7 (GenomeWeb News) - Underwriters of Alnylam Pharmaceuticals' initial public offering have exercised an over-allotment option, the company said today.


The underwriters have purchased an additional 750,000 shares of common stock at the IPO price of $6 per share, less an underwriting discount of $.42 per share.


Alnylam's initial public offering, first announced in February, is for 5,000,000 shares of common stock.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.